Michel Bensadoun<\/strong> - The market is quite dynamic, especially in the current economic climate. What is incomprehensible is how little support there is from the public authorities. MR B.<\/strong> - The taxation of medical conferences and incentives penalises the profession without bringing in any significant revenue. MR B. <\/strong>- According to our barometer for the first quarter of 2013, these measures, including those allowing up to 50 % to be taxed on the amount allocated to an incentive operation, will have a negative impact on agencies' sales. 54 % of them estimate this drop at around 10 %. In addition, with Brussels having ruled in favour of Paris for its system of VAT on the margin, French agencies find themselves at a disadvantage compared with their European counterparts. Companies will no longer be able to reclaim their VAT if they use a French organiser!<\/p>","protected":false},"excerpt":{"rendered":"
The various constraints are a real economic brake! It's becoming complicated to organise a medical congress in France in the face of competition from other destinations such as Vienna or Barcelona.<\/p>\nCould you tell us more?<\/h2>\n
As a result of the industry's lobbying of the government and parliament, the rebate rate for pharmaceutical companies was set at 75 %, compared with the initial rate of 50 %.
When you consider that congresses organised by the medical sector account for 45 % of the congresses held in France and \u20ac465.4 million in direct and indirect economic spin-offs, it's easy to see the impact of this measure...
Another impact on the medical sector is the obligation of transparency.<\/p>\nDo you have any idea of the repercussions on the industry?<\/h2>\n